This registry study, called Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF), assesses real-world patterns of care and outcomes in patients with atrial fibrillation. The registry will describe this patient population with regards to demographics, clinical factors, risk stratification, and geographic regions. In particular, attention will be focused on the utilization, effectiveness, and safety of antithrombotic therapies in the prevention of stroke. The registry is designed to identify reasons and risk factors for non-receipt of anticoagulation (AC) therapy, as well as reasons why AF patients who are prescribed AC therapy do not take them.
A total of 10,000 patients will participate in this study from approximately 170 centers. The Reading Hospital has completed enrollment in the ORBIT-AF study, but it continues to conduct follow-up visits with the patients who are already enrolled in the study.
For more information, please call the Clinical Trials Office at 484-628-4308 or visit clinicaltrials.gov.